In Vitro Activities of Eight Antifungal Drugs against 55 Clinical Isolates of Fonsecaea spp
- 1 April 2010
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 54 (4) , 1636-1638
- https://doi.org/10.1128/aac.01655-09
Abstract
The in vitro activities of eight antifungal drugs against clinical isolates of Fonsecaea pedrosoi (n = 21), Fonsecaea monophora (n = 25), and Fonsecaea nubica (n = 9) were tested. The resulting MIC(90)s for all strains (n = 55) were as follows, in increasing order: posaconazole, 0.063 mu g/ml; itraconazole, 0.125 mu g/ml; isavuconazole, 0.25 mu g/ml; voriconazole, 0.5 mu g/ml; amphotericin B, 2 mu g/ml; caspofungin, 2 mu g/ml; anidulafungin, 2 mu g/ml; and fluconazole, 32 mu g/ml.This publication has 20 references indexed in Scilit:
- Difficult mycoses of the skin: advances in the epidemiology and management of eumycetoma, phaeohyphomycosis and chromoblastomycosisCurrent Opinion in Infectious Diseases, 2009
- Successful treatment of chromoblastomycosis of 36 years duration caused by Fonsecaea monophoraMedical Mycology, 2009
- In vitroactivity of antifungal drugs againstCladophialophoraspecies associated with human chromoblastomycosisMedical Mycology, 2009
- Genetic diversity and species delimitation in the opportunistic genusFonsecaeaMedical Mycology, 2009
- Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatmentMedical Mycology, 2009
- Isavuconazole: A New and Promising Antifungal Triazole for the Treatment of Invasive Fungal InfectionsFuture Microbiology, 2008
- Management of chromoblastomycosis: novel perspectivesCurrent Opinion in Infectious Diseases, 2006
- Posaconazole treatment of refractory eumycetoma and chromoblastomycosisRevista do Instituto de Medicina Tropical de São Paulo, 2005
- Treating chromoblastomycosis with systemic antifungalsExpert Opinion on Pharmacotherapy, 2004
- Chromoblastomycosis: clinical and mycologic experience of 51 casesMycoses, 2001